Drug Approval | November 01, 2021
Sun Pharma's Winlevi available in the US
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
